|
|
Article: AEterna Gains Positive Results In Phase III Trial Of Impavido.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Patients participating in a Phase III study of Impavido, a proposed treatment for the severe skin disease cutaneous Leishmaniasis, had a higher cure rate than patients in the placebo group.
Impavido (miltefosine) is made by Frankfurt, Germany-based Zentaris AG, a subsidiary of AEterna Laboratories Inc., of Quebec City, Quebec. The product recently was approved in India as the first oral treatment for the life-threatening visceral form of Leishmaniasis. Impavido is pending approval in Bangladesh.
Study results released by AEterna Tuesday involved the cutaneous form of the disease, prominent in certain South American countries. ...